Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
This Study is
No Longer Enrolling
Details
Age
Adult
Phase
Not Applicable - Describes studies without FDA-defined phases, including studies of devices or behavioral interventions.
Type of Study
Treatment
Scope
National
Locations
Dana Farber Cancer Institute
MD Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
The Ohio State University Comprehensive Cancer Center
UCLA, Jonsson Cancer Center
University of Colorado Hospital
University of Michigan Comprehensive Cancer Center
Study ID
Protocol Number: 16-2230
More information available at ClinicalTrials.gov: NCT02973997
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers